PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of viroljBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleVirology JournalJournal Front Page
 
Virol J. 2010; 7: 215.
Published online 2010 September 8. doi:  10.1186/1743-422X-7-215
PMCID: PMC2944167

Alternative way to test the efficacy of swine FMD vaccines: measurement of pigs median infected dose (PID50) and regulation of live virus challenge dose

Abstract

Foot-and -mouth disease to pigs is serious recently around the world. "Vaccination prevention" is still an important policy. OIE specifies 10,000 TCID50(0.2 ml) of virulent virus for challenge test in pigs to test the potency of FMD vaccine by intradermal route inoculating the virus in the heel bulbs of one foot or by intramuscular route administering into one site of the neck behind the ear. Convenience and speediness are available in the process of potency test of commercial FMD vaccine. We selected the route of "administering into one site of the muscular part of the neck behind the ear" because of convenience and speediness. However, it was difficult to infect control pigs even up to 100,000TCID50, so we changed the challenged virus from cell-passaged strain to suckling mice-passaged one, measured its PID50 (pigs median infected dose) and defined the virus challenge dose as 1000PID50. Meanwhile, we arranged the number of control pigs from two to three for easy evaluation.

Findings

Foot-and-mouth disease (FMD) is an extremely contagious viral disease of cloven-hoofed domesticated as well as wild animals and has a great potential for causing severe economic loss. The causal agent, FMD virus (FMDV), is a member of the genus Aphthovirus in the family Picornaviridae and occurs as seven distinct serotypes throughout the world: A, O, C, Asia1 and South African Territories (SAT) 1-3. Vaccination is the most important control and eradication strategy for FMD, especially the oil-adjuvant vaccine in developing countries [1-4]. The different processes for preparing vaccines against viral diseases are comprised by a sequence of steps which, although different in accordance with particular virus and processes selected, may be classified as follows: virus production, virus inactivation and vaccine formulation.

In recent years, the pigs infected with FMD have been reported around the Chinese mainland, such as Chinese Taipei, Chinese Hong Kong [5-9]. Furthermore, import of vaccines are not only expensive, they are not always suitable. Therefore research into vaccine development and improvement is vital. In order to test vaccine efficacy in swine, the protected rate as well as ID50 and the challenge dose need to be determined. The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE terrestrial manual 2009, Chapter 2.1.5 Foot-and-mouth disease) lists a number of criteria for testing FMD vaccines in pigs. These include challenge in the heel bulb of 1 foot with 104 TCID50 of FMDV titered in a suitable pig cell culture systems or administering into one site of the muscular part of the neck behind the ear. However, "challenge in the heel bulb" is too laborious and time-consuming during the commercial vaccine potency tests because more than hundred pigs need to be captured at the same time, so we choose "administering into one site of the muscular part of the neck behind the ear" as our challenge route. Most of the FMD vaccine companies in China select BHK-21 cell lines to propagate the swine vaccine virus strain, and we also use BHK-21 passaged virus as the challenge strain to keep the consistency. Unfortunately, we did not achieve a good result in our factual operation due to the control pigs not appear clinical symptoms while challenged intramuscularly with 10000 TCID50(TCID50 = 8.0), which means that the tests did not go on. Therefore we tried to change the virus from cell-passaged strain to suckling mice-passaged strain and hope to get a good result.

FMDV OH/99 strain was isolated from pigs [10] and propagated in suckling mice as the challenge strain and in baby hamster kidney (BHK-21) cells as the vaccine strain. The suckling mice of 2-3-day-old were subcutaneously injected with 0.1 ml of OH/99 strain and passed for 3-5 passages. Upon death (16-20 hr post-infection), the bodies were collected and grinded.

Pigs median infected dose (PID50) was determined with suckling mice's passaged strain OH/99. The strain was series decuple diluted from 10-1 to 10-10. Forty 2-month-old pigs, sero-negative for FMDV antibodies, were randomly divided into ten groups. Each group including four pigs was housed in a separate room and inoculated at the ear-root-neck area with 2 ml virus-dilution per pig from 10-1 to 10-10 respectively. After ten days clinical observation, the PID50 was calculated according to Karber method. The experiment was repeated for the dilutions 10-5 to 10-8. The PID50 was calculated to be 6.5. The data were shown in Table Table1.1. The repeated data were the same.

Table 1
Data for calculating PID50

The virus culture liquids were treated by ethylenimmine 0.035 M/L at 30°C during 24 h for virus inactivation, then the inactivation was stopped by 0.04 M sodium thiosulphate [11]. Following the operation guidelines, the inactivated FMDV antigen was emulsified with Montanide ISA 206(Seppic, France)oil.

Sixteen 2-month-old pigs, sero-negative for FMDV, were intramuscular inoculated at the ear-root-neck area with 2 ml inactivated vaccine respectively, and three pigs were bred without vaccination in the same room as negative control. Sera samples were collected at 14 dpv (days post vaccination) and 28 dpv to assay the antibody against FMDV serotype O using a standard LPB-ELISA (Liquid phase blocking-ELISA).

To demonstrate vaccine efficacy, all 19 pigs were challenged intramuscularly with 1000 PID50/2 ml of FMDV OH/99 suckling mice passaged strain at the ear-root-neck area after 28 dpv and FMD symptoms were monitored for 10 days.

The results of the antibody response titrations of 14 dpv and 28 dpv of vaccinated pigs by LPB-ELISA and protective effect in pigs were recorded in table table2.2. The average titer at 14 dpv and 28 dpv was 1.50 and 1.84 respectively. At 2-4 days after challenge, blisters were observed on three animals of the negative control group. Sixteen vaccinated pigs were completely protected.

Table 2
The results of the sera titers of 14 dpv and 28 dpv of vaccinated pigs by LPB-ELISA and protective effect in swine challenged with OH/99

There are two prevention and eradication strategies for FMD. "Slaughter policy" is definitely widely used in the developed countries, but "vaccination policy" is carried out in developing countries due to high FMD prevalence and economic reasons. The FMD, in most of the spontaneous epidemic areas, was found to spread from cattle to cattle. However, in recent years, pigs' FMD circulated. China is one of the largest swine breeding countries and pork plays a very important role in people's daily life. In view of the above mentioned arguments, the development of a cheap FMD vaccine for swine is warranted and urgently needed. After all, swine and cattle are different species, and they have different immune system. The antibody response level against FMDV type O in swine is lower and weaker than which in cattle [12]. Normally, 10000 ID50 of virus challenge dose was used in cattle FMD vaccine efficacy testing and 10000TCID50 was used in pigs FMD vaccine efficacy testing (OIE terrestrial manual 2009, Chapter 2.1.5 Foot-and-mouth disease). However, in our experiments, 10000 ID50 dose was too strong in pigs as even high efficient vaccines did not protect the animals but 10000TCID50 was too weak in pigs even 105 TCID50 only cause part of control pigs occurring clinical signs, which was difficult to judge the result's credibility while "administering into one site of the muscular part of the neck behind the ear "(interior data). The pig's original FMD virus was stronger and could be used as the challenge strain, but a large amount of the materials was limited to obtain. The suckling mice passaged virus was used here as challenge strain to solve the problem. Comparatively, the suckling mice passaged virus was easier to propagate, and the virulence equal to original virus but stronger than BHK-21 passaged one, and infected all control pigs in our repeatedly experiments. Therefore, the suckling mice passaged virus was applied in our intramuscular FMD vaccine potency test and a challenge dose was considered to be 1000 PID50.

Two of control pigs were arranged in OIE terrestrial manual 2009. We found that sometimes one pig occurred FMD clinical symptoms but another not while challenge even with original virus. The reason was not clear. But how to evaluate the potency test when 1/2 of control is positive? So we set three pigs as control. The test will be appropriate when 2/3 of control pigs generated disease.

The antibody titer is one of referenced criteria to evaluate vaccine potency as it is positively linked with protection rate, but it is influenced by factors such as vaccine's antigen content, animal's individual status, virus challenge dose and route [13-15]. The LPB-ELISA assay was recognized as one of the standard methods to detect antibody. The kit (bought from WRLforFMD, Britain) was handled according to manufacture's instruction. When the titer is higher than 1.65, it means positive. Lower than 0.6 means negative. The range from 0.78 to 1.65 is a gray area, indicated that some animals can be protected, others can not. In our result, only one pig's (No.8) antibody titer (1.34) of 28 dpv was lower than 1.65, which belong to higher titer of gray area, and it was protected in the challenge. Although these data criteria were designated to cattle, we referred it to pigs here.

However, the antibody titers could not instead of PD50 test. There are two ways to test FMD vaccine potency: PD50 test(within Europe) or PG test (Protection against Generalization [16]. Here, we accepted the ratio of vaccine protection which used widely in South America. Sixteen are vaccinated for 28 days, and other three are negative control. The vaccine final products will be qualified when the protected rate is equal or more than 12/16, and sickness rate for control is equal or more than 2/3. Here, the vaccine's protection rate was 16/16.

From above, we measured pigs median infected dose (PID50), used suckling mice passaged virus as intramuscular challenged strain, and determined 1000 PID50 as the challenge dose to test the efficacy of swine FMD vaccine.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZXL is the leader of the study group. DL carried out the experiments and wrote the manuscript. ZJL and PS carried out the animal tests. BXX and YLC propagated the FMDV strain. YFF detected all the sera titers. All authors read and approved the final manuscript.

Acknowledgements

This work has been supported by "National key Technology R&D program of China, No. 2006BAD06A10 and No. 2006BAD06A03", ''Chinese national 973 project, No.2005CB523201.''

References

  • Balamurugan V, Kumar RM, Suryanarayana VV. Past and present vaccine development strategies for the control of foot-andmouth disease. Acta Virol. 2004;48(4):201–14. [PubMed]
  • Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004;17:465–493. doi: 10.1128/CMR.17.2.465-493.2004. [PMC free article] [PubMed] [Cross Ref]
  • Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, Dungu B, Amanfu W. Veterinary vaccines and their use in developing countries. Rev Sci Tech Off Int Epizoot. 2007;26(1):179–201. [PubMed]
  • Mason PW, Chinsangaram J, Moraes MP, Mayr GA, Grubman MJ. Engineering better vaccines for foot-and-mouth disease. Dev Biol. 2003;114:79–88. [PubMed]
  • Chen J, Zhao M, Hui K, Leung F. Molecular characterization of foot-and-mouth disease virus in Hong Kong during 2001-2002. Virus Genes. 2006;32:139–143. doi: 10.1007/s11262-005-5848-x. [PubMed] [Cross Ref]
  • Dunn CS, Donaldson AI. Natural adaption to pigs of a Taiwanese isolate of foot-and-mouth disease virus. Vet Rec. 1997;141:174–175. [PubMed]
  • Feng Q, Chen X, Ma O, Liu Y, Ding M, Collins RA, Ko LS, Xing J, Lau LT, Yu AC, Chen J. Serotype and VP1 gene sequence of a foot-and-mouth disease virus from Hong Kong. Biochem Biophys Res Commun. 2003;302(4):715–21. doi: 10.1016/S0006-291X(03)00250-X. [PubMed] [Cross Ref]
  • (18/02/2009, Chinese Taipei fmdv type O in swine.) http://www.oie.int
  • Yang PC, Chu RM, Chung WB, Sung HT. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet Rec. 1999;145:731–734. [PubMed]
  • Liu G, Liu Z, Xie Q. Generation of an infectious cDNA clone of an FMDV strain isolated from swine. Virus Res. 2004;104:157–164. doi: 10.1016/j.virusres.2004.04.002. [PubMed] [Cross Ref]
  • Bahnemann HG. The inactivation of foot and mouth disease virus by ethyleneimine and propyleneimine. Zbl Vet Med. 1973;B20:356–360. [PubMed]
  • Li D, Liu Z, Sun P. The efficacy of FMD vaccine reduced non-structural proteins with a mAb against 3B protein. Vet Res Commun. 2010;34:445–457. doi: 10.1007/s11259-010-9419-9. [PubMed] [Cross Ref]
  • Hamblin C, Armstrong RM, Hedger RS. A rapid enzyme-linked immunosorbent assay for the detection of foot-and-mouth disease virus in epithelial tissues. Vet Microbiol. 1984;9:435–443. doi: 10.1016/0378-1135(84)90064-6. [PubMed] [Cross Ref]
  • Hamblin C, Barnet ITR, Hedger RS. A new enzyme-linked immunosorbent assay(ELISA) for the detection of antibodies against foot-and-mouth disease virus. Journal of Immunological Methods. 1986;93:123–129. doi: 10.1016/0022-1759(86)90442-4. [PubMed] [Cross Ref]
  • Van Maanen C, Terpstra C. Comparison of a liquid-phase blocking sandwich ELISA and a serum neutralization test to evalute immunity in potency tests for foot-and-mouth disease. Vaccines. 1989;124:111–119. [PubMed]
  • Doel TR. FMD vaccine. Virus Research. 2003;91:8182–8199. doi: 10.1016/S0168-1702(02)00261-7. [PubMed] [Cross Ref]

Articles from Virology Journal are provided here courtesy of BioMed Central